metastatic breast cancer

Roche gets FDA green light for breast cancer drug Itovebi
Pharmaphorum
Fri, 10/11/24 - 09:34 am
Roche
FDA
Itovebi
metastatic breast cancer
Daiichi Sankyo launches first DTC ad for Enhertu, representing shift toward patient-centric oncology campaigns
Medical Marketing and Media
Sun, 09/22/24 - 09:46 pm
Daiichi Sankyo
AstraZeneca
breast cancer
metastatic breast cancer
Enhertu
DTC ads
ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases
Clinical Trials Arena
Tue, 09/17/24 - 11:20 am
ESMO
breast cancer
Daiichi Sankyo
Enhertu
metastatic breast cancer
clinical trials
6 first-half 2024 oncology data readouts to watch
BioSpace
Mon, 02/26/24 - 11:20 am
oncology
clinical trials
Daiichi Sankyo
AstraZeneca
Enhertu
metastatic breast cancer
Gilead Sciences
Trodelvy
bladder cancer
GSK
Zejula
Jemperli
ovarian cancer
Roche
tiragolumab
Tecentriq
non-small cell lung cancer
Cue Biopharma
CUE-101
head and neck cancer
Elicio Therapeutics
ELI-002
solid tumors
Roche reports positive Phase III data for breast cancer therapy
Clinical Trials Arena
Tue, 12/5/23 - 09:56 am
Roche
clinical trials
inavolisib
metastatic breast cancer
breast cancer
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
BioSpace
Tue, 10/3/23 - 07:28 pm
BriaCell Therapeutics
Bria-IMT
immune checkpoint inhibitors
metastatic breast cancer
Odonate Pulls MBC Drug Candidate and Closes Shop
BioSpace
Mon, 03/22/21 - 10:04 pm
Odonate Therapeutics
Tesetaxel
metastatic breast cancer
Athenex features real patients in first oncology campaign as it readies key breast cancer filing
Fierce Pharma
Wed, 07/1/20 - 11:00 am
oncology
Athenex
metastatic breast cancer
patients
Odonate Therapeutics announces completion of enrollment in CONTESSA metastatic breast cancer trial
Pharmaceutical Business Review
Tue, 10/22/19 - 10:35 am
Odonate Therapeutics
metastatic breast cancer
clinical trials
Tesetaxel
Lilly cancer push boosted by survival benefit to key drug
Biopharma Dive
Tue, 07/30/19 - 11:31 am
Eli Lilly
Verzenio
metastatic breast cancer
clinical trials
AstraZeneca's share dilution gamble on Daiichi drug pays off
Biopharma Dive
Thu, 05/9/19 - 10:49 am
AstraZeneca
Daiichi Sankyo
trastuzumab deruxtecan
metastatic breast cancer
MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin for metastatic breast cancer
Endpoints
Wed, 02/6/19 - 09:48 am
Macrogenics
metastatic breast cancer
margetuximab
clinical trials
Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission
CP Wire
Thu, 06/7/18 - 12:07 pm
Pfizer
talazoparib
BRCA-mutant breast cancer
breast cancer
metastatic breast cancer
FDA
EMA
priority review
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Mon, 06/4/18 - 09:31 am
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Endpoints
Sun, 06/3/18 - 10:29 am
Roche
taselisib
fulvestrant
metastatic breast cancer
ASCO 2018
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
Sat, 06/2/18 - 10:55 pm
ASCO 2018
taselisib
fulvestrant
metastatic breast cancer
estrogen-receptor cancer
Breast Cancer Cells Use In-House Recycling To Survive After Spreading
Forbes
Tue, 05/22/18 - 06:03 pm
breast cancer
metastatic breast cancer
autophagy
Novartis
Pfizer
AstraZeneca and Merck Present Updated Overall Survival Data for Lynparza in gBRCA-mutated HER2-Negative Metastatic Breast Cancer
CP Wire
Mon, 04/16/18 - 09:04 am
AstraZeneca
Merck
Lynparza
metastatic breast cancer
AACR
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
Thu, 03/15/18 - 09:55 am
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
Fri, 01/12/18 - 10:39 am
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer

Pages